SCHEMBL5409655

SCHEMBL5409655

COc1ccccc1/C=C/S(=O)(=O)O.Cc1cc(Cl)ccc1C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
NFE2L2 Q16236 7/20 0.46
ANO1 Q5XXA6 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALOX5 P09917 1/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
PTGES2 Q9H7Z7 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4618136 0.91 NFE2L2 (0.48) NPC1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5424985 0.89 ABCB1 (0.46) NFE2L2SMN1; SMN2ALOX5PTGS1PTGS2
SCHEMBL5416380 0.87 AR (0.49) NPC1LMNACYP1A2CYP3A4MAPT
SCHEMBL5420996 0.86 NFE2L2 (0.41) NPC1MAPTHPGDNFE2L2SMN1; SMN2
SCHEMBL27739103 0.86 NFE2L2 (0.41) NPC1MAPTHPGDNFE2L2SMN1; SMN2
SCHEMBL5416929 0.83 PTGES2 (0.48) NPC1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5409216 0.83 AR (0.49) NPC1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL5415469 0.82 PTGS2 (0.43) NPC1CYP1A2CYP3A4MAPTHPGD
SCHEMBL27738953 0.82 PTGS2 (0.43) NPC1CYP1A2CYP3A4MAPTHPGD
SCHEMBL5417239 0.81 MAPT (0.43) NPC1LMNAMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 NPC1 1099/4885LMNA 1178/4885CYP1A2 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.